US2015359773A1PendingUtilityA1

Combination methods and compositions including sleep therapeutics for treating mood

48
Individually held — no corporate assignee on recordPriority: Sep 26, 2012Filed: Sep 25, 2013Published: Dec 17, 2015
Est. expirySep 26, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Seth Feuerstein
A61M 21/02A61M 21/00A61K 36/35A61K 31/4985A61K 31/202A61K 31/437A61K 45/06A61P 25/24A61B 5/165
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising an omega-3 fatty acid formulation and a sleep-inducing agent. 
     
     
         2 . The composition of  claim 1 , wherein the sleep-inducing agent is a non-benzodiazepine hypnotic. 
     
     
         3 . The composition of  claim 2 , wherein the non-benzodiazepine hypnotic is eszopiclone or zolpidem. 
     
     
         4 . The composition of  claim 3  which is substantially free of an antidepressant. 
     
     
         5 . A method of treating depression comprising the administration of an anti-depressant effective amount of a pharmaceutical composition according to  claim 1  to a patient in need thereof. 
     
     
         6 . A method according to  claim 5  wherein said pharmaceutical composition is effective for the treatment of depression even in the absence of an antidepressant. 
     
     
         7 . A method according to  claim 5  wherein said depression is treatment-resistant depression. 
     
     
         8 . A method according to  claim 5  wherein said patient shows a PHQ-9 categorical improvement. 
     
     
         9 . A pharmaceutical composition comprising an antidepressant and a sleep-inducing agent. 
     
     
         10 . The composition of  claim 9 , wherein the sleep-inducing agent is a non-benzodiazepine hypnotic. 
     
     
         11 . The composition of  claim 10 , wherein the non-benzodiazepine hypnotic is eszopiclone or zolpidem. 
     
     
         12 . The composition of  claim 10  which is substantially free of an omega-3 fatty acid formulation. 
     
     
         13 . A method of treating depression comprising the administration of an anti-depressant effective amount of a pharmaceutical composition according to  claim 9  to a patient in need thereof. 
     
     
         14 . A method according to  claim 13  wherein said pharmaceutical composition is effective for the treatment of depression even in the absence of an omega-3 fatty acid formulation. 
     
     
         15 . A method according to  claim 13  wherein said depression is treatment-resistant depression. 
     
     
         16 . A method according to  claim 13  wherein said patient shows a PHQ-9 categorical improvement. 
     
     
         17 . A method of treating depression comprising the administration of an insomnia therapy program to a patient suffering from depression. 
     
     
         18 . The method of  claim 17  further comprising administration to the patient an antidepressant in an amount effective to treat depression in combination with said insomnia therapy program. 
     
     
         19 . The method of  claim 17  further comprising administration to the patient an omega-3 fatty acid formulation in an amount effective to treat depression in combination with said insomnia therapy program. 
     
     
         20 . A method according to  claim 17  wherein said patient shows a PHQ-9 categorical improvement.

Join the waitlist — get patent alerts

Track US2015359773A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.